Adagene Inc ADR (ADAG) Stock Price, Quote & News

Company Profile

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/met...

Industry: Biotechnology

Sector: Healthcare

Phone: 86 512 8777 3632

Website: www.adagene.com

Address:

Building C14, 4th Floor No. 218, Xinghu Street Suzhou Industrial Park, Suzhou, China

WraithIcey Feb. 2 at 7:37 PM

$ADAG has outperformed peers in the biomedical & genetics sector on a relative basis, hinting at selective investor interest even in tough market conditions:.

0 · Reply

WraithIcey Feb. 2 at 7:35 PM

$ADAG The company’s lead programs, including a conditionally masked CTLA-4 antagonist , are advancing clinical trials. Successful progression in clinical stages can materially de-risk the biotech valuation and unlock value.,

0 · Reply

WraithIcey Feb. 2 at 7:35 PM

$ADAG

0 · Reply

peepthestamp Jan. 29 at 11:54 PM

$ADAG -Aging well 👀

0 · Reply

StockScanners Jan. 27 at 3:41 AM

$ADAG reached 2.66

1 · Reply

SadyK189 Jan. 27 at 3:03 AM

Top Stocks to watch tomorrow 2 / 2: $ADAG $GUTS $DRMA $SCNI $SONM ADAG:Looking good on daily chart. Key support at 1.80 - 2.05. Next key level to test is 3- 3.30. Currently at 2.46 GUTS: Good close of 4hours candle. 1.85 - 2.05 is acting acting as key support zone. Next key level to test is 3.1 - 3.35. Currently at 2.60 DRMA: Getting up on 4hours chart. Key support at 2.3 - 2.55. It can test 3.8 - 4.1 zone again. Currently at 3.07 SCNI is moving slowly and steadily but nicely on 4hours chart. Key support at 0.87 - 0.92. Next key level to test is 1.4 - 1.55. Currently at 1.12 SONM: Looking good on daily chart. Key support at 6.4 - 6.8. Next key level to test is 8.45 - 8.75. Currently at 7.68

0 · Reply

StockScanners Jan. 24 at 5:12 AM

$ADAG keep watch if this holds above 2.30

0 · Reply

peepthestamp Jan. 23 at 11:47 PM

$ADAG

0 · Reply

topstockalerts Jan. 23 at 8:58 PM

Top Gainers PT2 $QCLS $ADAG $CHRS $ANL $KUST

0 · Reply

topstockalerts Jan. 23 at 6:34 PM

Top Gainers PT2 $QCLS $ADAG $WORX $CHRS $KUST

0 · Reply

Adagene Provides Business Update and 2026 Objectives

Dec 16, 2025, 7:00 AM EST - 7 weeks ago

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Nov 13, 2025, 7:00 AM EST - 2 months ago

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Sep 16, 2025, 8:00 AM EDT - 5 months ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Sep 5, 2025, 9:55 AM EDT - 5 months ago

Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Sep 3, 2025, 9:05 AM EDT - 5 months ago

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Aug 26, 2025, 8:05 AM EDT - 5 months ago

Adagene to Participate in Two Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Jul 15, 2025, 7:00 AM EDT - 7 months ago

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Jul 8, 2025, 7:00 AM EDT - 7 months ago

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Jul 1, 2025, 7:00 AM EDT - 7 months ago

Adagene announces up to $25 million strategic investment from Sanofi

May 27, 2025, 7:30 AM EDT - 9 months ago

Adagene to Present at Jefferies Global Healthcare Conference 2025

May 22, 2025, 5:05 PM EDT - 9 months ago

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Apr 23, 2025, 10:05 AM EDT - 10 months ago

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 11 months ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 8:00 AM EDT - 11 months ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Mar 6, 2025, 8:00 AM EST - 11 months ago

Adagene to Present at Leerink's Global Healthcare Conference 2025

Feb 27, 2025, 8:00 AM EST - 1 year ago

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Jan 29, 2025, 6:14 AM EST - 1 year ago

CD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,

Jan 21, 2025, 5:00 PM EST - 1 year ago

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Nov 7, 2024, 10:01 AM EST - 1 year ago

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 16, 2024, 3:01 AM EDT - 1 year ago

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

May 22, 2024, 4:45 PM EDT - 1 year ago

Adagene to Present at Investor Conferences in June

Mar 29, 2024, 9:00 AM EDT - 2 years ago

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 2 years ago

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Feb 27, 2024, 8:00 AM EST - 2 years ago

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 9, 2024, 6:00 AM EST - 2 years ago

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Jan 16, 2024, 5:01 PM EST - 2 years ago

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Jan 4, 2024, 5:00 AM EST - 2 years ago

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Sep 7, 2023, 6:00 AM EDT - 2 years ago

Adagene to Present at Investor and Scientific Conferences in September

Aug 31, 2023, 7:32 AM EDT - 2 years ago

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

May 4, 2023, 9:00 AM EDT - 2 years ago

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

Apr 28, 2023, 7:00 AM EDT - 3 years ago

Adagene Announces Updates to its Board of Directors

Apr 18, 2023, 9:17 AM EDT - 3 years ago

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Mar 28, 2023, 4:30 PM EDT - 3 years ago

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 14, 2023, 6:00 PM EDT - 3 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

Mar 5, 2023, 7:39 PM EST - 3 years ago

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

Jan 9, 2023, 7:00 AM EST - 3 years ago

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

Jan 5, 2023, 4:01 PM EST - 3 years ago

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

Dec 16, 2022, 6:30 AM EST - 3 years ago

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Nov 21, 2022, 4:05 PM EST - 3 years ago

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

Nov 10, 2022, 9:05 AM EST - 3 years ago

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Oct 11, 2022, 4:03 PM EDT - 3 years ago

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November

Sep 10, 2022, 4:13 AM EDT - 3 years ago

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

WraithIcey Feb. 2 at 7:37 PM

$ADAG has outperformed peers in the biomedical & genetics sector on a relative basis, hinting at selective investor interest even in tough market conditions:.

0 · Reply

WraithIcey Feb. 2 at 7:35 PM

0 · Reply

WraithIcey Feb. 2 at 7:35 PM

$ADAG

0 · Reply

peepthestamp Jan. 29 at 11:54 PM

$ADAG -Aging well 👀

0 · Reply

StockScanners Jan. 27 at 3:41 AM

$ADAG reached 2.66

1 · Reply

SadyK189 Jan. 27 at 3:03 AM

0 · Reply

StockScanners Jan. 24 at 5:12 AM

$ADAG keep watch if this holds above 2.30

0 · Reply

peepthestamp Jan. 23 at 11:47 PM

$ADAG

0 · Reply

topstockalerts Jan. 23 at 8:58 PM

Top Gainers PT2 $QCLS $ADAG $CHRS $ANL $KUST

0 · Reply

topstockalerts Jan. 23 at 6:34 PM

Top Gainers PT2 $QCLS $ADAG $WORX $CHRS $KUST

0 · Reply

godiswatching Jan. 23 at 6:15 PM

$YYAI $ADAG $LIF $GIBO 🚀 🚀 https://www.insidertrades.com/alerts/nasdaq-yyai-insider-buying-and-selling-2026-01-23/

1 · Reply

topstockalerts Jan. 23 at 4:51 PM

$ADAG Strong momentum setup shaping up. Buyers are defending these levels and pushing higher. Could see continuation from here.

0 · Reply

Stock_Catcher Jan. 23 at 4:45 PM

$ADAG Scans

0 · Reply

justiceforb_85 Jan. 15 at 6:56 PM

$ADAG moving based on $AGEN?

1 · Reply

BillionerOfKing Jan. 15 at 6:40 PM

$ADAG Current Stock Price: $1.92

0 · Reply

SuperGreenToday Dec. 24 at 2:49 PM

$ADAG

0 · Reply

justiceforb_85 Dec. 17 at 11:08 PM

$ADAG decided to add. Muzastotug with promising data and likely best-in-class. Possible BO candidate given $MRK partnership.

0 · Reply

ZacksResearch Dec. 17 at 2:24 PM

$ADAG rips higher — FDA Fast Track just lit the fuse 🚀 Adagene jumped 13.8% after the FDA granted Fast Track Status to muzastotug in combination with pembrolizumab for MSS metastatic colorectal cancer, putting this program on an accelerated regulatory path. Full catalyst breakdown here 👉 https://www.zacks.com/stock/news/2805441/fda-grants-fast-track-designation-to-adags-colorectal-cancer-drug?cid=sm-stocktwits-2-2805441-teaser-25131&ADID=SYND_STOCKTWITS_TWEET_2_2805441_TEASER_25131

0 · Reply

ZacksResearch Dec. 17 at 1:24 PM

Fast Track boost for $ADAG — but is it enough? 🚀 FDA granted Fast Track to muzastotug with Keytruda for MSS mCRC without current or active liver metastases, sparking a 13.8% share surge. Yet, ADAG's shares are down 6.9% over the past year, trailing the industry's 16.3% rise. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2805441/fda-grants-fast-track-designation-to-adags-colorectal-cancer-drug?cid=sm-stocktwits-2-2805441-body-25129&ADID=SYND_STOCKTWITS_TWEET_2_2805441_BODY_25129

0 · Reply

justiceforb_85 Dec. 17 at 3:13 AM

$ADAG wondering how muzastotug compares to botensilimab by $AGEN which is further along in development?

1 · Reply

stevenryl86 Dec. 17 at 2:05 AM

$ADAG I dig further, ADG126 interim data in early 2026 should highlight for potential buyout.

1 · Reply

Market Cap	129.61M
Revenue (ttm)	100,000.00
Net Income (ttm)	-33.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-33,420.00%
Debt to Equity Ratio	0.12

Volume	102,700
Avg Vol	195,208
Day's Range	N/A - N/A
Shares Out	47.13M
Stochastic %K	84%
Beta	0.71
Analysts	Strong Sell
Price Target	$7.25